EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

One of these therapies, rituximab, a chimeric monoclonal antibody against human CD20 (hCD20; a B-cell-specific surface marker), depletes B cells and has been effective in several autoimmune ...

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior by drugmakers.

The company needs to win over haematologists to its new treatment, as biosimilar versions of rituximab are expected to hit the European market in 2017, and could be close behind in the US.

The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela ...

Eagle Pharmaceuticals (EGRX) announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds ...

Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...

• In advanced-stage HL, reduction of chemotherapy or radiotherapy after a negative interim PET scan is probably beneficial for overall survival. • Treatment escalation with rituximab after a positive ...